Rabalkem‑DSR is a fixed‑dose combination capsule comprising Domperidone 10 mg, a prokinetic that stimulates gastrointestinal motility, and Rabeprazole 20 mg, a proton pump inhibitor (PPI) that suppresses stomach acid. Marketed by Alkem Laboratories, it is commonly used to relieve acid reflux and ulcer symptoms by both reducing gastric acidity and enhancing gut movement.

Mechanism of Action

• Rabeprazole acts by inhibiting the proton pump (H⁺/K⁺‑ATPase) in stomach lining cells, significantly reducing acid secretion and allowing irritated tissue to heal .

• Domperidone selectively blocks peripheral dopamine D₂ receptors in the gastrointestinal tract and the brain’s chemoreceptor trigger zone (CTZ), thereby speeding up gastric emptying, improving motility, and reducing nausea and vomiting.

  Uses

  Rabalkem‑DSR is indicated for:

  • Gastroesophageal reflux disease (GERD) and reflux oesophagitis

  • Peptic ulcer disease

  • Other upper GI motility disorders such as functional dyspepsia, diabetic gastroparesis, or non-ulcer reflux (NERD)

  • Prevention or relief of nausea and vomiting related to chemotherapy, radiotherapy, or migraine therapy

    Adverse Effects

    Common side effects (usually transient):

    • Gastrointestinal: diarrhea, abdominal pain, flatulence, nausea, constipation

    • Neurological/general: headache, dizziness, weakness, drowsiness or insomnia, and nasal congestion or pharyngitis .

    Less frequent but important risks:

    • Long-term acid suppression by rabeprazole may cause low magnesium, vitamin B12 deficiency, increased risk of bone fractures, and possible gastrointestinal infections like Clostridioides difficile or pneumonia .

    • Domperidone may rarely cause extrapyramidal symptoms or cardiac arrhythmias, particularly at high doses or in the elderly; QT prolongation risk is low but should be considered